Federated Hermes
ITOS

Federated Hermes’s iTeos Therapeutics ITOS Stock Holding History

Federated Hermes’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,117
Closed -$31.8K – 2137
2024
Q3 		$31.8K Buy
3,117
+1,312
+73% +$20K ﹤0.01% 1713
2024
Q2 		$26.8K Sell
1,805
-885
-33% -$12.7K ﹤0.01% 1690
2024
Q1 		$36.7K Sell
2,690
-254
-9% -$2.77K ﹤0.01% 1642
2023
Q4 		$32.2K Buy
2,944
+2,882
+4,648% +$28.6K ﹤0.01% 1697
2023
Q3 		$679 Sell
62
-2,314
-97% -$29.6K ﹤0.01% 2028
2023
Q2 		$31.5K Sell
2,376
-10,153
-81% -$145K ﹤0.01% 1735
2023
Q1 		$171K Sell
12,529
-48,024
-79% -$860K ﹤0.01% 1608
2022
Q4 		$1.18M Sell
60,553
-102,198
-63% -$2M ﹤0.01% 1081
2022
Q3 		$3.1M Sell
162,751
-24,243
-13% -$558K 0.01% 783
2022
Q2 		$3.85M Sell
186,994
-32,278
-15% -$766K 0.01% 753
2022
Q1 		$7.06M Buy
219,272
+123,474
+129% +$4.49M 0.02% 697
2021
Q4 		$4.46M Buy
+95,798
New +$3.19M 0.01% 844

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Federated Hermes's ITOS Position: Q4 2024 in Review

Federated Hermes sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 3,117 shares — an estimated $31.8K sold.

Federated Hermes first reported a position in ITOS in Q4 2021 and held it in 12 quarters. The position peaked at $7.06M in Q1 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Federated Hermes reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 3,117 iTeos Therapeutics shares in Q4 2024, an estimated $31.8K.
  • Federated Hermes first reported a position in iTeos Therapeutics in Q4 2021 and held it in 12 quarters.
  • Federated Hermes's iTeos Therapeutics position peaked at $7.06M in Q1 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.